SynthesisPloS one2014
The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Meta-Analysis: Enhanced Liver Fibrosis (ELF) Test for Identifying Significant Fibrosis, Advanced Fibrosis, and Cirrhosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.Alimentary pharmacology & therapeutics · 2026Pooled it
- Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.Hepatology international · 2017Guideline
- Fibrotic Disease: from Signaling Pathways and Biomarkers to Molecular Imaging.Molecular imaging and biology · 2025Review
- Characterization of an At-Risk Population for Nonalcoholic Fatty Liver Disease (NAFLD) in a Primary Care Setting Along the U.S.-Mexico Border.Journal of transcultural nursing : official journal of the Transcultural Nursing Society · 2025Review
- Alcohol Use Disorder and Alcohol-Associated Liver Disease: New Definitions, Screening, and Treatment.Gastroenterology & hepatology · 2024Article
- Chronic Liver Disease - What's New?Indian journal of pediatrics · 2024Review
- Towards an adiposity-related disease framework for the diagnosis and management of obesities.Reviews in endocrine & metabolic disorders · 2023Review
- Gas6 in chronic liver disease-a novel blood-based biomarker for liver fibrosis.Cell death discovery · 2023Article
- A salivary biomarker panel to detect liver cirrhosis.iScience · 2023Article
- Identifying Patients with Nonalcoholic Fatty Liver Disease in Primary Care: How and for What Benefit?Journal of clinical medicine · 2023Review
- Recent advances in NAFLD: current areas of contention.Faculty reviews · 2023Review
- Liver fibrosis quantification.Abdominal radiology (New York) · 2022Review
- Fibroblast Growth Factor 21 as a Marker of Prediabetes in Patients with Non-alcoholic Fatty Liver Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Breath-Taking Perspectives and Preliminary Data toward Early Detection of Chronic Liver Diseases.Biomedicines · 2021Review
- Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives.International journal of molecular sciences · 2021Review
- Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease.World journal of gastroenterology · 2020Review
- Serum Scoring and Quantitative Magnetic Resonance Imaging in Intestinal Failure-Associated Liver Disease: A Feasibility Study.Nutrients · 2020Article
- Review
- Work up of fatty liver by primary care physicians, review.Annals of medicine and surgery (2012) · 2020Review
- Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease.Translational gastroenterology and hepatology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe enhanced liver fibrosis test (ELF) has been shown to accurately predict significant liver fibrosis in several liver diseases.
aimsTo perform a meta-analysis to assess the performance of the ELF test for the assessment of liver fibrosis. STUDY: Electronic and manual searches were performed to identify studies of the ELF test. After methodological quality assessment and data extraction, pooled estimates of the sensitivity, specificity, area under the receiver operating characteristic curve (AUROC), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and summary receiver operating characteristics (sROC) were assessed systematically. The extent of heterogeneity and reasons for it were assessed.
resultsNine studies were identified for analysis. The pooled sensitivity, specificity, positive LR, negative LR, and DOR values of ELF test, for assessment of significant liver fibrosis, were 83% (95% CI=0.80-0.86), 73% (95% CI=0.69-0.77), 4.00 (95% CI=2.50-6.39), 0.24 (95% CI=0.17-0.34), and 16.10 (95% CI=8.27-31.34), respectively; and, for evaluation of severe liver fibrosis, were 78% (95% CI=0.74-0.81), 76% (95% CI=0.73-0.78), 4.39 (95% CI=2.76-6.97), 0.27 (95% CI=0.16-0.46), and 16.01 (95% CI: 7.15-35.82), respectively; and, for estimation of cirrhosis, were 80% (95% CI=0.75-0.85), 71% (95% CI=0.68-0.74), 3.13 (95% CI=2.01-4.87), 0.29 (95% CI=0.19-0.44), and 14.09 (95% CI: 5.43-36.59), respectively.
conclusionsThe ELF test shows good performance and considerable diagnostic value for the prediction of histological fibrosis stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.